1. Metronidazole, the prototype nitroimidazole antiprotozoal agent, is selectively toxic to anaerobic and microaerophilic organisms but not to aerobic mammalian cells at therapeutic doses. Which property of the drug best explains this selectivity?
A) It is a fully active drug that binds a receptor expressed only on anaerobic organisms
B) It directly inhibits a ribosomal subunit unique to anaerobic protozoa
C) It is a prodrug requiring reductive activation by low-potential electron donors (such as ferredoxin and pyruvate:ferredoxin oxidoreductase) found in anaerobes but not in aerobic host cells
D) It chelates iron required by anaerobic organisms but spared by mammalian cells
E) It is activated only at the high oxygen tensions found in aerobic mammalian tissue
ANSWER: C
Rationale:
Metronidazole is a prodrug. In anaerobic and microaerophilic organisms, low-potential electron carriers (ferredoxin in anaerobic bacteria and Giardia; pyruvate:ferredoxin oxidoreductase, the enzyme that decarboxylates pyruvate using ferredoxin as electron acceptor, in Trichomonas and Entamoeba) donate electrons to the drug nitro group, reducing it to a reactive nitroso radical anion that causes DNA strand breaks. Aerobic mammalian cells lack these low-potential donors, so the drug is not activated in host tissue, giving the selectivity described.
Option A: Option A is incorrect: metronidazole is not a directly active receptor ligand; it must be reductively activated intracellularly.
Option B: Option B is incorrect: the lethal target is DNA, not a ribosomal subunit, and metronidazole is not a protein-synthesis inhibitor.
Option D: Option D is incorrect: the mechanism is reductive radical generation, not iron chelation.
Option E: Option E is incorrect and inverts the actual biology; activation requires the low-oxygen, low-redox-potential environment of anaerobes, and high oxygen tension prevents radical formation.
2. A patient is prescribed oral metronidazole for bacterial vaginosis. Which counseling instruction is most important to prevent the characteristic disulfiram-like reaction (flushing, nausea, vomiting, headache, and tachycardia caused by acetaldehyde accumulation)?
A) Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose
B) Take the drug only on an empty stomach to avoid the reaction
C) Avoid all dairy products during the treatment course
D) Limit dietary tyramine to prevent a hypertensive reaction
E) Avoid sun exposure because the reaction is triggered by ultraviolet light
ANSWER: A
Rationale:
Metronidazole inhibits acetaldehyde dehydrogenase (the enzyme that clears acetaldehyde generated from ethanol). When alcohol is ingested, acetaldehyde accumulates and produces a disulfiram-like reaction. Patients must avoid all alcohol, including hidden sources such as mouthwashes and many liquid medications, during therapy and for 48 hours after the last dose (72 hours for tinidazole, which has a longer half-life).
Option B: Option B is incorrect: timing relative to food does not cause or prevent this reaction.
Option C: Option C is incorrect: dairy restriction is irrelevant to nitroimidazoles and is not part of metronidazole counseling.
Option D: Option D is incorrect: tyramine-triggered hypertensive crisis is associated with monoamine oxidase inhibitors, not with metronidazole.
Option E: Option E is incorrect: the reaction is driven by acetaldehyde accumulation after alcohol intake, not by ultraviolet light exposure.
3. A patient is treated with metronidazole for an amebic liver abscess (extraintestinal infection with Entamoeba histolytica). To achieve full eradication and prevent relapse, what additional step is required?
A) Add a second tissue agent that also acts systemically, such as tinidazole, given simultaneously
B) Repeat the metronidazole course twice before considering the infection cleared
C) Add an aerobic gram-negative antibiotic to cover polymicrobial spread
D) Follow metronidazole with a luminal agent (such as diloxanide furoate or iodoquinol) to eliminate intestinal cyst carriage
E) Add a corticosteroid to reduce abscess-associated inflammation
ANSWER: D
Rationale:
Metronidazole reaches high tissue concentrations and clears invasive trophozoites in the abscess, but it does not reliably eradicate Entamoeba histolytica cysts persisting in the intestinal lumen. A luminal agent (diloxanide furoate or iodoquinol), which acts within the gut lumen, must follow the metronidazole course to clear cyst carriage and prevent relapse and ongoing transmission.
Option A: Option A is incorrect: tinidazole is another nitroimidazole with the same tissue-directed activity and does not substitute for a luminal agent.
Option B: Option B is incorrect: repeating tissue therapy does not address luminal cysts, which are the source of relapse.
Option C: Option C is incorrect: amebic liver abscess is not a polymicrobial pyogenic process, and aerobic gram-negative coverage is not indicated.
Option E: Option E is incorrect: routine corticosteroids are not part of standard amebic abscess therapy and can be harmful if the diagnosis is mistaken.
4. A traveler returning from West Africa is diagnosed with human African trypanosomiasis (sleeping sickness, caused by Trypanosoma brucei gambiense). Before any antitrypanosomal drug is selected, which step is mandatory?
A) Obtain a chest radiograph to exclude pulmonary involvement
B) Perform a lumbar puncture to stage the disease, because cerebrospinal fluid findings determine whether central-nervous-system-penetrating therapy is required
C) Obtain a 24-hour urine collection to grade renal function before dosing
D) Begin empiric melarsoprol immediately without staging to avoid delay
E) Perform liver biopsy to confirm the diagnosis histologically
ANSWER: B
Rationale:
Human African trypanosomiasis progresses through stage 1 (hemolymphatic) and stage 2 (encephalitic). Stage is defined by cerebrospinal fluid examination (pleocytosis above 5 white blood cells per microliter, or trypanosomes seen in cerebrospinal fluid), so lumbar puncture is mandatory before treatment selection. Stage 1 drugs need not cross the blood-brain barrier, whereas stage 2 requires central-nervous-system-penetrating agents; choosing therapy without staging risks treatment failure.
Option A: Option A is incorrect: chest radiography does not stage the disease or guide drug choice.
Option C: Option C is incorrect: 24-hour urine collection is not the staging step, though urinalysis is monitored during suramin therapy.
Option D: Option D is incorrect and dangerous: melarsoprol carries a high risk of fatal reactive encephalopathy and is reserved for confirmed stage 2 disease, never given empirically without staging.
Option E: Option E is incorrect: diagnosis rests on parasite detection in blood, lymph node aspirate, or cerebrospinal fluid, not liver biopsy.
5. A child with acute Chagas disease (American trypanosomiasis, caused by Trypanosoma cruzi) requires antiparasitic treatment. Which agent is the preferred first-line drug globally?
A) Suramin
B) Pyrimethamine
C) Sodium stibogluconate
D) Metronidazole
E) Benznidazole
ANSWER: E
Rationale:
Benznidazole, a nitroimidazole derivative activated by Trypanosoma cruzi nitroreductases, is the preferred first-line agent for Chagas disease worldwide; cure rates exceed 80 percent in the acute phase, and pediatric patients tolerate it better than adults. Nifurtimox is the principal second-line alternative.
Option A: Option A is incorrect: suramin treats stage 1 African trypanosomiasis (T. b. rhodesiense), not Chagas disease.
Option B: Option B is incorrect: pyrimethamine is used for toxoplasmosis, not Chagas disease.
Option C: Option C is incorrect: sodium stibogluconate is a pentavalent antimonial used for leishmaniasis.
Option D: Option D is incorrect: metronidazole treats anaerobic protozoa such as Giardia, Entamoeba, and Trichomonas, and has no role against Trypanosoma cruzi.
6. An immunocompetent patient is diagnosed with visceral leishmaniasis (kala-azar), which is fatal if untreated. According to World Health Organization guidance for most settings, which agent is the treatment of choice?
A) Liposomal amphotericin B
B) Oral metronidazole
C) Intravenous suramin
D) Oral pyrimethamine with sulfadiazine
E) Intramuscular melarsoprol
ANSWER: A
Rationale:
Liposomal amphotericin B is the treatment of choice for visceral leishmaniasis in immunocompetent patients in most settings. It binds ergosterol-like membrane sterols in the parasite and concentrates in the reticuloendothelial system (liver, spleen, bone marrow), precisely where Leishmania amastigotes reside in macrophages, while limiting nephrotoxicity relative to conventional amphotericin.
Option B: Option B is incorrect: metronidazole has no activity against Leishmania.
Option C: Option C is incorrect: suramin is an antitrypanosomal agent for stage 1 African trypanosomiasis, not leishmaniasis.
Option D: Option D is incorrect: pyrimethamine-sulfadiazine treats toxoplasmosis.
Option E: Option E is incorrect: melarsoprol is used for stage 2 African trypanosomiasis and is not a leishmaniasis agent.
7. A patient with AIDS is treated for toxoplasmic encephalitis with pyrimethamine plus sulfadiazine. Which agent must always be co-administered to prevent the hematologic toxicity (leukopenia, thrombocytopenia, megaloblastic anemia) caused by pyrimethamine?
A) Folic acid (the oxidized form)
B) Folinic acid (leucovorin)
C) Vitamin B12 (cyanocobalamin)
D) Pyridoxine (vitamin B6)
E) Ferrous sulfate
ANSWER: B
Rationale:
Pyrimethamine inhibits dihydrofolate reductase, the enzyme that regenerates tetrahydrofolate. Folinic acid (leucovorin) is reduced folate that bypasses the dihydrofolate reductase block in mammalian cells, preventing the dose-limiting hematologic toxicity, while the parasite (which must synthesize its own folate) remains susceptible.
Option A: Option A is incorrect and is the classic error: folic acid is the oxidized form and still requires dihydrofolate reductase to become active, so it does not bypass the block and must not be substituted for folinic acid.
Option C: Option C is incorrect: vitamin B12 does not bypass the dihydrofolate reductase block.
Option D: Option D is incorrect: pyridoxine addresses isoniazid-related neuropathy, not pyrimethamine marrow toxicity.
Option E: Option E is incorrect: iron does not protect against the folate-pathway blockade caused by pyrimethamine.
8. A patient receiving intravenous pentamidine for cutaneous leishmaniasis must have blood glucose checked before and after each dose. Which adverse effect explains this monitoring requirement?
A) Hyperkalemia from renal potassium retention
B) Hyperthyroidism from iodine release
C) Profound hypertension from catecholamine surge
D) Hypoglycemia from direct pancreatic beta-cell toxicity causing insulin release
E) Acute hemolysis in glucose-6-phosphate dehydrogenase deficiency
ANSWER: D
Rationale:
Pentamidine is directly toxic to pancreatic beta cells. Early in therapy, beta-cell injury causes uncontrolled insulin release and hypoglycemia; with prolonged exposure, beta-cell destruction can produce hyperglycemia and diabetes mellitus. Because of the hypoglycemia risk, blood glucose is monitored before and after each administration.
Option A: Option A is incorrect: pentamidine is associated with nephrotoxicity and can cause hyperkalemia in some contexts, but the glucose-monitoring requirement is driven by its beta-cell effect, not potassium handling.
Option B: Option B is incorrect: pentamidine does not cause hyperthyroidism.
Option C: Option C is incorrect: pentamidine more commonly causes hypotension, not a hypertensive catecholamine surge.
Option E: Option E is incorrect: dose-dependent hemolysis in glucose-6-phosphate dehydrogenase deficiency is characteristic of primaquine and related 8-aminoquinolines, not pentamidine.
9. Tinidazole is often selected over metronidazole for giardiasis or trichomoniasis. Which property of tinidazole accounts for this preference?
A) It is active against aerobic organisms that metronidazole cannot reach
B) It does not produce a disulfiram-like reaction with alcohol
C) Its longer half-life (about 12 to 14 hours) and better gastrointestinal tolerability permit effective single-dose therapy, improving adherence
D) It is the only nitroimidazole that crosses the blood-brain barrier
E) It carries no teratogenic concern and is preferred in the first trimester of pregnancy
ANSWER: C
Rationale:
Tinidazole is a second-generation nitroimidazole with a longer half-life (about 12 to 14 hours) and improved gastrointestinal tolerability compared with metronidazole. These properties allow single-dose regimens (for example, tinidazole 2 g once) that achieve cure rates equal to or better than multiday metronidazole courses for giardiasis and trichomoniasis, improving adherence.
Option A: Option A is incorrect: like metronidazole, tinidazole acts on anaerobic and microaerophilic organisms, not aerobes.
Option B: Option B is incorrect: tinidazole also causes a disulfiram-like reaction, and alcohol must be avoided for an even longer interval (about 72 hours) because of its longer half-life.
Option D: Option D is incorrect: metronidazole itself penetrates the central nervous system well, so this is not a distinguishing tinidazole advantage.
Option E: Option E is incorrect: nitroimidazoles are generally avoided in the first trimester for non-life-threatening indications, so tinidazole offers no first-trimester safety advantage.
10. A patient with stage 2 human African trypanosomiasis (encephalitic stage, with the parasite established in the central nervous system) is mistakenly treated with suramin. Why will this therapy fail?
A) Suramin is rapidly degraded by central-nervous-system esterases before it can act
B) Suramin is only active against Trypanosoma cruzi, not the African subspecies
C) Suramin does not cross the blood-brain barrier, so it cannot reach parasites in the central nervous system; stage 2 disease requires a central-nervous-system-penetrating agent
D) Suramin requires reductive activation that occurs only in the bloodstream
E) Suramin is inactivated by the high protein content of cerebrospinal fluid
ANSWER: C
Rationale:
Suramin is a polysulfonated naphthylurea that binds extensively to plasma proteins and does not cross the blood-brain barrier. It is therefore effective only in stage 1 (hemolymphatic) disease; once trypanosomes have entered the central nervous system in stage 2, suramin cannot reach them and a central-nervous-system-penetrating agent (such as melarsoprol, eflornithine, or the nifurtimox-eflornithine combination) is required.
Option A: Option A is incorrect: suramin failure in stage 2 reflects failure to enter the central nervous system, not central esterase degradation.
Option B: Option B is incorrect: suramin treats stage 1 African trypanosomiasis (notably T. b. rhodesiense); it is not a Trypanosoma cruzi agent.
Option D: Option D is incorrect: suramin is not a prodrug requiring reductive activation.
Option E: Option E is incorrect: the limitation is failure to cross the blood-brain barrier, not inactivation within cerebrospinal fluid.
11. Eflornithine (difluoromethylornithine), an irreversible inhibitor of ornithine decarboxylase (the rate-limiting enzyme of polyamine synthesis), is effective against stage 2 Trypanosoma brucei gambiense but not against Trypanosoma brucei rhodesiense. What explains this subspecies selectivity?
A) T. b. gambiense has much slower turnover of ornithine decarboxylase, so irreversible inhibition is sustained long enough to be lethal, whereas T. b. rhodesiense rapidly resynthesizes the enzyme
B) Eflornithine cannot cross the blood-brain barrier in rhodesiense infection
C) T. b. rhodesiense lacks ornithine decarboxylase entirely
D) Eflornithine is activated only by an enzyme unique to gambiense bloodstream forms
E) T. b. rhodesiense uses an alternative carbon source that bypasses polyamine synthesis
ANSWER: A
Rationale:
Eflornithine irreversibly inhibits ornithine decarboxylase. Because Trypanosoma brucei gambiense turns the enzyme over slowly, the irreversible block persists long enough to halt polyamine synthesis and kill the parasite. Trypanosoma brucei rhodesiense resynthesizes ornithine decarboxylase rapidly, restoring activity before the drug can be lethal, which accounts for its resistance.
Option B: Option B is incorrect: eflornithine does cross the blood-brain barrier, which is why it treats stage 2 gambiense disease.
Option C: Option C is incorrect: rhodesiense possesses ornithine decarboxylase; the difference is turnover rate, not absence of the enzyme.
Option D: Option D is incorrect: eflornithine is not a prodrug requiring subspecies-specific activation.
Option E: Option E is incorrect: both subspecies depend on polyamine synthesis for division; the distinction lies in enzyme turnover, not an alternative metabolic bypass.
12. A patient stabilized on warfarin (a vitamin K antagonist anticoagulant) is started on metronidazole. Which monitoring action is most important, and why?
A) Monitor serum potassium, because metronidazole induces renal potassium wasting
B) Monitor blood glucose, because metronidazole directly injures pancreatic beta cells
C) Monitor the QTc interval, because metronidazole markedly prolongs cardiac repolarization
D) Monitor serum creatinine, because metronidazole requires dose reduction in renal impairment
E) Monitor the international normalized ratio, because metronidazole inhibits CYP2C9 and potentiates the anticoagulant effect of warfarin
ANSWER: E
Rationale:
Metronidazole inhibits CYP2C9, the cytochrome P450 enzyme that metabolizes the more active S-enantiomer of warfarin. Reduced clearance raises warfarin exposure and potentiates anticoagulation, so the international normalized ratio must be monitored and the warfarin dose adjusted when the drugs are combined.
Option A: Option A is incorrect: metronidazole does not cause clinically important renal potassium wasting.
Option B: Option B is incorrect: beta-cell toxicity and glucose monitoring describe pentamidine, not metronidazole.
Option C: Option C is incorrect: marked QTc prolongation is characteristic of pentavalent antimonials, not metronidazole.
Option D: Option D is incorrect: although metronidazole dose is reduced in severe hepatic impairment, it does not require renal dose adjustment, and creatinine monitoring is not the key warfarin-interaction concern.
13. Miltefosine, the first oral agent effective against visceral leishmaniasis, has an elimination half-life of about 7 days, with drug detectable for more than 5 weeks after the last dose. Which counseling point follows directly from this pharmacokinetic property in a woman of childbearing potential?
A) She must take the drug strictly on an empty stomach to ensure absorption
B) She should expect a disulfiram-like reaction if she drinks alcohol
C) Because miltefosine is teratogenic (Category X) and has a long half-life, highly effective contraception is mandatory during treatment and for 5 months afterward
D) She must avoid all sun exposure for the duration of therapy
E) She requires weekly glucose monitoring because of beta-cell toxicity
ANSWER: C
Rationale:
Miltefosine is teratogenic (Category X). Its long elimination half-life (about 7 days, with drug present for more than 5 weeks after the final dose) means teratogenic exposure persists well beyond the treatment course, so highly effective contraception is required during treatment and for 5 months afterward, and a negative pregnancy test should be confirmed before prescribing.
Option A: Option A is incorrect: miltefosine is in fact better tolerated when taken with food, which reduces nausea.
Option B: Option B is incorrect: the disulfiram-like reaction is a nitroimidazole effect, not a miltefosine effect.
Option D: Option D is incorrect: photosensitivity precautions are not the defining counseling issue for miltefosine.
Option E: Option E is incorrect: beta-cell toxicity with glucose monitoring describes pentamidine, not miltefosine.
14. A patient receiving a pentavalent antimonial (sodium stibogluconate) for leishmaniasis requires baseline and periodic electrocardiograms. Which feature of these agents drives the need for cardiac monitoring?
A) They cause rapid atrial fibrillation through vagal withdrawal
B) They prolong the QTc interval, creating a risk of torsades de pointes
C) They precipitate complete heart block by calcium-channel antagonism
D) They cause coronary vasospasm leading to myocardial ischemia
E) They induce malignant hyperthermia during administration
ANSWER: B
Rationale:
Pentavalent antimonials (Sb(V)) are reduced to the active trivalent form (Sb(III)) inside macrophages and inhibit the parasite trypanothione system. Among their serious toxicities, QTc prolongation is well recognized and can lead to torsades de pointes, so electrocardiographic monitoring is required during therapy (pancreatitis, hepatotoxicity, and nephrotoxicity are the other major adverse effects).
Option A: Option A is incorrect: the cardiac concern is repolarization prolongation, not vagally mediated atrial fibrillation.
Option C: Option C is incorrect: antimonials do not act as calcium-channel antagonists or characteristically cause complete heart block.
Option D: Option D is incorrect: coronary vasospasm is not the recognized antimonial cardiotoxicity.
Option E: Option E is incorrect: malignant hyperthermia is triggered by volatile anesthetics and succinylcholine, not by antimonials.
15. Before each dose of suramin given for stage 1 human African trypanosomiasis, a specific bedside test must be performed and reviewed. Which monitoring step is required, and what finding halts further dosing?
A) Check capillary blood glucose; a value below 60 mg/dL halts dosing
B) Check a 12-lead electrocardiogram; a prolonged QTc halts dosing
C) Check serum transaminases; a threefold rise halts dosing
D) Check a urinalysis for proteinuria; proteinuria above 2+ halts further suramin dosing because of nephrotoxicity
E) Check a complete blood count; thrombocytopenia halts dosing
ANSWER: D
Rationale:
Suramin is nephrotoxic, and proteinuria is an early marker of renal injury. Urinalysis is therefore performed before every dose, and proteinuria above 2+ is a contraindication to further suramin administration. (A small test dose is also given before the first full dose because of the rare risk of fatal anaphylaxis on first exposure.)
Option A: Option A is incorrect: hypoglycemia monitoring before and after dosing applies to pentamidine, not suramin.
Option B: Option B is incorrect: QTc monitoring is required for pentavalent antimonials, not suramin.
Option C: Option C is incorrect: transaminase-driven dose halting is not the defining suramin monitoring rule; renal monitoring by urinalysis is.
Option E: Option E is incorrect: marrow suppression with complete-blood-count monitoring is characteristic of eflornithine, not suramin.
16. The pyrimethamine-sulfadiazine regimen for toxoplasmosis works by sequential blockade of the parasite folate-synthesis pathway. Sulfadiazine inhibits dihydropteroate synthase (an early step), and pyrimethamine inhibits dihydrofolate reductase (a downstream step). Applying the same enzymatic logic, why does adding folinic acid protect the patient without rescuing Toxoplasma gondii?
A) Folinic acid inhibits dihydropteroate synthase in the parasite, deepening the blockade
B) Folinic acid increases renal clearance of pyrimethamine, lowering host drug levels
C) Folinic acid is taken up only by the parasite, where it is converted to a toxic metabolite
E) Folinic acid is already-reduced folate that bypasses the dihydrofolate reductase block in mammalian cells, which can use it, whereas Toxoplasma must synthesize folate de novo and cannot
ANSWER: E
Rationale:
Pyrimethamine blocks dihydrofolate reductase, the enzyme that produces tetrahydrofolate. Folinic acid is already-reduced folate, so mammalian cells, which can take up preformed folate, bypass the block and are protected from marrow toxicity. Toxoplasma gondii must synthesize folate de novo and cannot use host folate effectively, so it remains susceptible; this is the same sequential-blockade logic given in the stem, now applied to the rescue agent.
Option A: Option A is incorrect: folinic acid does not inhibit dihydropteroate synthase; it supplies reduced folate.
Option B: Option B is incorrect: the protective effect is metabolic bypass, not altered pyrimethamine clearance.
Option C: Option C is incorrect: folinic acid is not selectively converted to a parasite toxin; it rescues host cells.
Option D: Option D is incorrect: the mechanism is not protein-binding displacement of sulfadiazine.
17. A patient with stage 2 Trypanosoma brucei rhodesiense infection is treated with melarsoprol (an organoarsenical that crosses the blood-brain barrier). Concurrent prednisolone is given. What is the principal reason for the corticosteroid, and what is the underlying risk?
A) Prednisolone prevents the disulfiram-like reaction that melarsoprol causes with alcohol
B) Prednisolone reduces (but does not eliminate) the risk of post-treatment reactive encephalopathy, an inflammatory syndrome that is fatal in roughly half of affected patients
C) Prednisolone reverses the hypoglycemia that melarsoprol predictably causes
D) Prednisolone is given to counteract melarsoprol-induced QTc prolongation
E) Prednisolone is required to activate melarsoprol into its trypanocidal form
ANSWER: B
Rationale:
Melarsoprol causes post-treatment reactive encephalopathy in roughly 5 to 10 percent of treated patients, and this inflammatory syndrome is fatal in about half of those affected. Co-administered prednisolone (1 mg/kg/day) reduces but does not eliminate that risk, which is why it is given alongside melarsoprol for stage 2 disease.
Option A: Option A is incorrect: the disulfiram-like reaction is a nitroimidazole effect, and prednisolone does not prevent it.
Option C: Option C is incorrect: predictable hypoglycemia is a pentamidine effect, not a melarsoprol effect requiring steroid reversal.
Option D: Option D is incorrect: melarsoprol toxicity is dominated by encephalopathy and thrombophlebitis, not QTc prolongation, and steroids would not address an arrhythmia mechanism.
Option E: Option E is incorrect: melarsoprol does not require corticosteroid-dependent activation; it acts by binding trypanothione through its trivalent arsenic moiety.
18. A patient acquires visceral leishmaniasis in the Bihar region of India, where pentavalent antimonial resistance in Leishmania donovani has reached 60 percent or higher. Based on this regional resistance pattern, which treatment choice is most appropriate?
A) Sodium stibogluconate, because resistance does not affect clinical response
B) Suramin, which is the standard agent for South Asian visceral leishmaniasis
C) Pyrimethamine-sulfadiazine, the regional first-line regimen
D) Liposomal amphotericin B or miltefosine, because widespread antimonial resistance has made antimonials effectively obsolete for South Asian visceral leishmaniasis
E) Melarsoprol, the preferred agent once antimonials fail
ANSWER: D
Rationale:
In Bihar and neighboring areas, antimonial resistance in Leishmania donovani is so prevalent (60 percent or higher) that these drugs are effectively obsolete for South Asian visceral leishmaniasis. Liposomal amphotericin B and oral miltefosine are the appropriate first-line choices in this setting.
Option A: Option A is incorrect: high-level resistance directly compromises antimonial efficacy, so they should not be used here.
Option B: Option B is incorrect: suramin is an antitrypanosomal agent and has no role in leishmaniasis.
Option C: Option C is incorrect: pyrimethamine-sulfadiazine treats toxoplasmosis, not leishmaniasis.
Option E: Option E is incorrect: melarsoprol treats stage 2 African trypanosomiasis and is not a leishmaniasis agent.
19. The nifurtimox-eflornithine combination therapy (NECT) regimen was adopted by the World Health Organization in 2009 for stage 2 Trypanosoma brucei gambiense human African trypanosomiasis. Compared with eflornithine monotherapy, what advantage made NECT the standard of care?
A) It achieves equivalent efficacy while reducing the eflornithine drug burden and improving operational feasibility, by combining oral nifurtimox with a shortened eflornithine course
B) It is the only regimen that does not require the disease to be staged first
C) It eliminates the need for any parenteral drug administration
D) It is effective against stage 2 rhodesiense as well as gambiense disease
E) It removes the need for cerebrospinal fluid follow-up after treatment
ANSWER: A
Rationale:
NECT pairs oral nifurtimox with a shortened eflornithine course. It matches the efficacy of eflornithine monotherapy while lowering the eflornithine drug burden and improving feasibility in field conditions, which is why the World Health Organization adopted it as standard of care for stage 2 gambiense disease in 2009.
Option B: Option B is incorrect: staging by lumbar puncture remains mandatory; NECT does not bypass it.
Option C: Option C is incorrect: the eflornithine component is still parenteral, so the regimen is not fully oral (fexinidazole later provided the first all-oral option).
Option D: Option D is incorrect: NECT and eflornithine are selective for gambiense; rhodesiense stage 2 is treated with melarsoprol.
Option E: Option E is incorrect: post-treatment follow-up, including cerebrospinal fluid assessment, remains part of care and is not eliminated by NECT.
20. The BENEFIT trial (Benznidazole Evaluation for Interrupting Trypanosomiasis) studied benznidazole in patients with established chronic Chagas cardiomyopathy. Which result best summarizes its key finding and its clinical implication?
A) Benznidazole both cleared the parasite and reversed established cardiomyopathy, supporting universal treatment at any disease stage
B) Benznidazole had no detectable effect on parasite burden but improved cardiac outcomes
C) Benznidazole reduced parasite detection by polymerase chain reaction but did not reduce cardiac events or mortality over 5 years, raising questions about the benefit of treating established cardiomyopathy
D) Benznidazole increased cardiac mortality and is now contraindicated in all chronic infection
E) Benznidazole was found equivalent to nifurtimox specifically for acute congenital disease
ANSWER: C
Rationale:
BENEFIT showed that benznidazole reduced parasite detection by polymerase chain reaction but did not reduce cardiac events or mortality over 5 years of follow-up in patients with established Chagas cardiomyopathy. This dissociation between parasitologic and clinical endpoints is what raises questions about treating patients who already have advanced cardiac disease, even as guidelines still favor treating younger patients with indeterminate or early disease.
Option A: Option A is incorrect: the trial did not show reversal of established cardiomyopathy.
Option B: Option B inverts the result: parasite detection fell, while cardiac outcomes did not improve.
Option D: Option D is incorrect: the trial did not show increased cardiac mortality or establish a blanket contraindication.
Option E: Option E is incorrect: BENEFIT addressed chronic cardiomyopathy, not a head-to-head comparison with nifurtimox in acute congenital disease.
21. A trainee writing for pyrimethamine-sulfadiazine therapy substitutes folic acid for folinic acid, reasoning that both are "folate." Applying the folate-pathway logic established earlier in this set, why is this substitution a clinically meaningful error?
A) Folic acid is more potent than folinic acid and will cause folate toxicity
B) Folic acid rescues the parasite as well as the host, abolishing antiparasitic efficacy entirely
C) Folic acid and folinic acid are interchangeable, so the substitution has no clinical consequence
D) Folic acid is contraindicated because it directly inactivates sulfadiazine in plasma
E) Folic acid is the oxidized form that still requires dihydrofolate reductase to become active; because pyrimethamine blocks that enzyme, folic acid cannot bypass the block, so it fails to protect host marrow
ANSWER: E
Rationale:
Folic acid is the oxidized form of folate and must be reduced by dihydrofolate reductase before cells can use it. Because pyrimethamine blocks dihydrofolate reductase, folic acid cannot be activated and therefore cannot bypass the block to protect host marrow. Folinic acid is already-reduced folate, so it rescues host cells regardless of the enzyme block; this is exactly why folinic acid, not folic acid, must be used.
Option A: Option A is incorrect: the problem is failure to bypass the block, not excess potency or folate toxicity.
Option B: Option B is incorrect: the issue is host protection, not parasite rescue; Toxoplasma cannot use host folate effectively in any case.
Option C: Option C is incorrect and is the dangerous misconception the question targets: the two are not interchangeable.
Option D: Option D is incorrect: folic acid does not chemically inactivate sulfadiazine.
22. Melarsoprol (used in African trypanosomiasis), pentavalent antimonials (used in leishmaniasis), and nifurtimox (used in Chagas disease) all converge on one parasite-specific vulnerability that is absent in mammalian cells. Identifying this shared target, which pathway do they exploit?
A) The mammalian glutathione system, which these drugs deplete in host tissue
B) The trypanothione system, a parasite-specific redox pathway (using a glutathione-spermidine conjugate) that melarsoprol disrupts via arsenic binding, antimonials inhibit after reduction to Sb(III), and nifurtimox overwhelms with reactive oxygen species
C) The mammalian cytochrome P450 system, which all three drugs inhibit
D) The bacterial cell wall synthesis pathway shared by protozoa
E) The host folate-synthesis pathway targeted by sequential blockade
ANSWER: B
Rationale:
Trypanosoma and Leishmania species rely on trypanothione (a conjugate of glutathione and spermidine) rather than glutathione as their principal intracellular antioxidant, and on trypanothione reductase to keep it reduced. This pathway is absent in mammalian cells, making it a selective target: melarsoprol binds trypanothione through its arsenic moiety, pentavalent antimonials inhibit trypanothione reductase after reduction to Sb(III), and nifurtimox generates reactive oxygen species that overwhelm the system.
Option A: Option A is incorrect: the target is the parasite trypanothione system, not the mammalian glutathione system.
Option C: Option C is incorrect: shared cytochrome P450 inhibition is not the unifying mechanism of these three agents.
Option D: Option D is incorrect: protozoa do not have a bacterial cell wall, and these drugs do not act on cell wall synthesis.
Option E: Option E is incorrect: folate sequential blockade describes pyrimethamine-sulfadiazine, not these three trypanothione-targeting drugs.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.